Clinical Trial Update: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I trial evaluating CCT303-406 in relapsed or refractory HER2-positive solid tumors is active but not recruiting, including gastric cancer, breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Ovarian Cancer
• Sarcoma

Drugs mentioned

• CCT303-406

Snippet

Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Conditions: Solid Tumor, Gastric Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING